title: Preventing and managing antiretroviral drug resistance.
abstract: Development of resistance to antiretroviral drugs (ARVs) is a major impediment to optimum treatment of HIV-1 infection. Although resistance testing can help to select subsequent regimens when virologic failure occurs, cross-resistance, which affects all classes of ARVs, may make it more difficult to achieve optimum control of HIV. We have known for some time that our first choice of antiretroviral therapy offers the best chance to control HIV replication and that initial therapy should be selected with an eye on future options. Potency is the first line of defense against the development of resistance. Other factors that affect resistance development include: tolerability, potential for optimum adherence, and genetic and pharmacologic barriers to development of resistance. If resistance emerges, only a single drug may be affected initially, and a rapid change in ARVs may preserve the efficacy of other components. One cautionary note is that we can no longer assume that a patient's HIV is fully susceptible to all ARVs even in the initial regimen. Transmission of drug-resistant HIV means that the genetic composition may be that of an "experienced" virus with reduced susceptibility to ARVs. Resistance testing at the time of transmission is most likely to reveal this resistance, but over time the dominant genetic pattern may revert to wild-type, and be missed by resistance testing. Because "archived" resistant HIV may emerge quickly once treatment is initiated, we need to keep this in mind when selecting initial therapy.
authors.affiliation: Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA. dkuritzkes@partners.org
authors.forename: Daniel R
authors.initials: DR
authors.lastname: Kuritzkes
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D016903:Drug Monitoring; D024921:Drug Resistance, Multiple, Viral; D024882:Drug Resistance, Viral / Q000187:drug effects / Q000235:genetics; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000523:psychology / Q000821:virology; D015497:HIV-1 / Q000235:genetics; D006801:Humans; D008826:Microbial Sensitivity Tests; D017720:Molecular Epidemiology; D009154:Mutation / Q000235:genetics; D010349:Patient Compliance; D018579:Patient Selection; D010597:Pharmacogenetics; D010641:Phenotype; D017410:Practice Guidelines as Topic; D016016:Proportional Hazards Models; D012367:RNA, Viral / Q000235:genetics; D012307:Risk Factors; D013997:Time Factors; D017211:Treatment Failure; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D012367:RNA, Viral